Roivant Sciences (NASDAQ: ROIV) insider plans 200,000-share sale

Rhea-AI Filing Summary

Roivant Sciences Ltd. insider plans to sell 200,000 common shares under Rule 144. The shares are to be sold through Rockefeller Financial LLC on NASDAQ around 01/12/2026, with an aggregate market value of 4,383,694.07 and 695,491,615 common shares outstanding. The 200,000 shares were acquired on 01/12/2026 by exercising options originally granted on 04/20/2022, with payment made by wire.

Over the prior three months, the same seller, Eric Venker (c/o Roivant Sciences Ltd., London), completed multiple open-market sales of Roivant common shares. Individual transactions included 414,683 shares sold on 10/15/2025 for 7,021,429.14 and 318,282 shares sold on 10/16/2025 for 5,425,645.04, along with several other sales ranging from 7,051 to 200,000 shares. By signing the notice, the seller represents they do not know any undisclosed material adverse information about Roivant’s operations.

Insights

Equity capital markets analyst

Form 144 discloses a planned 200,000‑share Roivant insider sale following recent sizable sales.

The filing shows an insider-related holder planning to sell 200,000 Roivant Sciences common shares through Rockefeller Financial LLC on NASDAQ, with an indicated market value of 4,383,694.07. These shares come from stock options granted on 04/20/2022 and exercised on 01/12/2026, which is a typical pathway for equity compensation to convert into tradable stock.

The disclosure also lists several prior sales by Eric Venker in the last three months, including 414,683 shares sold on 10/15/2025 for gross proceeds of 7,021,429.14 and multiple additional blocks between 7,051 and 200,000 shares. Shares outstanding total 695,491,615, so each individual sale represents a small fraction of the company’s equity. This notice is informational and does not alter Roivant’s capital structure directly, since it reflects secondary market activity rather than new share issuance.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	200000	4383694.07	695491615	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	01/12/2026	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			200000	01/12/2026	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	10/13/2025	20727	336877.25
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	10/15/2025	414683	7021429.14
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	10/16/2025	318282	5425645.04
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	10/17/2025	118418	2020170.82
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	11/07/2025	200000	4043960.00
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	11/20/2025	7051	142923.77
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	12/09/2025	200000	4169131.30
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	12/23/2025	200000	4490540.00
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	12/24/2025	75000	1689750.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Roivant Sciences (ROIV) Form 144 filing disclose?

The filing discloses that an insider-related holder intends to sell 200,000 Roivant Sciences common shares under Rule 144, to be sold through Rockefeller Financial LLC on NASDAQ around 01/12/2026, with an indicated aggregate market value of 4,383,694.07.

Who is selling Roivant Sciences (ROIV) shares and how were they acquired?

The past sales and the planned sale relate to Eric Venker (addressed c/o Roivant Sciences Ltd. in London). The 200,000 shares covered by this notice were acquired as Common Shares on 01/12/2026 through an options exercise of grants dated 04/20/2022, with payment made by wire.

How many Roivant Sciences (ROIV) shares did this holder sell in recent months?

Over the past three months, the holder completed several sales of Roivant common shares, including 20,727 shares on 10/13/2025, 414,683 shares on 10/15/2025, 318,282 shares on 10/16/2025, and multiple additional trades of 7,051 to 200,000 shares through 12/24/2025, each with disclosed gross proceeds.

How many Roivant Sciences (ROIV) shares are outstanding compared with this Form 144 sale?

The table states that 695,491,615 common shares of Roivant Sciences are outstanding. The current Form 144 notice covers a planned sale of 200,000 shares, which is a small portion of the total shares outstanding.

What representation does the seller make about Roivant Sciences (ROIV) information?

By signing the notice, the seller represents that they do not know any material adverse information about Roivant Sciences’ current or prospective operations that has not been publicly disclosed, consistent with Rule 144 requirements described in the form.